Miruvor
Sign up
The short answer

What studies of speech therapy found

3papers on speech therapy
1 (few people)person in 1 study testing speech therapy alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty), for overall symptoms.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Speech therapy might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Speech therapy · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Daily life and health overall

Overall symptoms1 study · 1 (few people) person took part in speech therapy Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · after 3 months of follow-up (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of speech therapy on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. Post-COVID-19 paradoxical vocal cord movement and dysfunctional dysphonia: A clinical case. (2022)

    People in the study
    1 in the study
    Dose
    —
    Outcome
    symptoms
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. Case report: Dysphagia after COVID-19 infection in a stroke patient-Is neurostimulation a potential management?2023 · case report · 1 in the study
    Summary

    This case report described one 90-year-old man with stroke and post-COVID-19 dysphagia in a rehabilitation ward. He had been weaned from tube feeding 4 months after stroke onset; after COVID-19, a nasogastric tube was reinserted. Swallowing therapy with neurostimulation was given: rTMS at 500 pulses of 10 Hz and 90% resting motor threshold to bilateral pharyngeal cortices, plus NMES at 80 Hz and 12 mA, in a 1-h program 5 days per week for 2 weeks, with conventional swallowing training. Another 10 sessions of swallowing training containing rTMS and NMES were administered. There was no comparison group. Outcomes included feeding tube removal, VFSS findings, FOIS, oral intake, choking, weight, and lung infection. The feeding tube was removed after 20 treatment sessions; the nasogastric tube was removed on October 7, 2022, the 110th day after COVID-19 infection. The report noted improved oral movements, reduced drooling, better laryngeal elevation, stronger volitional cough, less post-swallowing choking, greater swallowing endurance, and improved swallowing ability with increased oral intake and fewer choking episodes. At discharge after the first neurostimulation admission, FOIS was 3 and the nasogastric tube was still necessary. A VFSS on October 7, 2022 showed good bolus transit, less premature leakage, delayed swallowing reflex, good hypopharynx elevation, penetration in thin and thick barium, trace aspiration in thin barium, and limited residue. At one month after tube removal, no lung infection was reported; the patient gained 2 kg after the last discharge.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime